National and Kapodistrian University of Athens
Επίπεδα VEGF σε πλευριτική συλλογή και περιφερικό δείγμα αίματος σε ασθενείς με καρκίνο πνεύμονα: η κλινική τους σημασία
Abstract
dc:descriptionThe primary objective of the present study was to prospectively evaluate the potential prognostic value of pretreatment vascular endothelial growth factor (VEGF) levels in serum and pleural fluid from patients with non-small cell lung carcinoma (NSCLC) presenting with malignant pleural effusion (MPE). We also aimed to investigate the diagnostic utility of serum VEGF levels in discriminating between patients with NSCLC and healthy individuals. Forty consecutive newly diagnosed NSCLC patients with MPE at presentation but without distant metastases, who were referred to the Oncology Unit G’PP of “Sotiria” General Hospital, Athens, Greece, between September 2009 and September 2013, were prospectively enrolled. Serum and pleural fluid VEGF levels were assayed by enzyme-linked immunoassay (ELISA). Serum VEGF levels were also measured in 50 controls with similar age and sex distribution (p=0.517 and p=0.795, respectively). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off value for serum VEGF to discriminate between patients and healthy subjects. Serum and pleural fluid VEGF levels were correlated with standard clinicopathological parameters, including gender, age, smoking history, performance status (PS), histological type of tumor and treatment response. The prognostic value of each variable for overall survival (OS) and progression-free survival (PFS) was assessed by univariate and multivariate Cox regression analysis.The median serum VEGF levels were significantly higher in patients as compared to healthy controls (p<0.001), while the optimal cut-off of serum VEGF was 375 pg/ml, with a sensitivity and specificity of 76.9% and 98.0%, respectively. Serum VEGF more than 375 pg/ml, pleural fluid VEGF over the median value and the presence of progressive disease, were all significantly associated with reduced OS and PFS, both in univariate and in multivariate analysis. A statistically significant correlation was also observed between serum and pleural fluid VEGF levels (p<0.001).The results of the present study suggest that serum VEGF levels may be useful in discriminating between patients with NSCLC and healthy individuals, and that increased pretreatment serum and pleural fluid levels of VEGF may be independent predictors of a worse survival in advanced-stage NSCLC patients. Future prospective studies are nevertheless needed to confirm these findings in larger patient cohorts and to further explore the potential value of these candidate biomarkers in predicting not only survival, but also response to targeted anti-angiogenic therapies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkiozos, Ioannis
- Γκιόζος, Ιωάννης
Subjects
dc:subject × 14- Αγγειακός ενδοθηλιακός αυξητικός παράγοντας (Vascular Endothelial Growth Factor, VEGF)
- Κακοήθης πλευριτική συλλογή
- Μη μικροκυτταρικός καρκίνος πνεύμονα (ΜΜΚΠ)
- Ορός
- Πλευριτικό υγρό
- Malignant pleural effusion
- Non - small cell lung cancer (NSCLC)
- Pleural fluid
- Serum
- Vascular endothelial growth factor (VEGF)
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35721